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2ABSTRACT
CD95 (also known as Fas) is the prototype of death receptors; however, evidence suggests that 
this receptor mainly implements non-apoptotic signaling pathways such as NF-B, MAPK, and 
PI3K that are involved in cell migration, differentiation, survival, and cytokine secretion. At 
least two different forms of CD95L exist. The multi-aggregated transmembrane ligand (m-
CD95L) is cleaved by metalloproteases to release a homotrimeric soluble ligand (s-CD95L). 
Unlike m-CD95L, the interaction between s-CD95L and its receptor CD95 fails to trigger 
apoptosis, but instead promotes calcium-dependent cell migration, which contributes to the 
accumulation of inflammatory Th17 cells in damaged organs of lupus patients and favors cancer 
cell invasiveness. Novel inhibitors targeting the pro-inflammatory roles of CD95/CD95L may 
provide attractive therapeutic options for patients with chronic inflammatory disorders or 
cancer. This review discusses the roles of the CD95/CD95L pair in cell migration and 
metastasis.
Keywords: Apoptosis, calcium, cytoskeleton, migration, TNF.
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3Introduction
Metastatic disease remains the main cause of mortality among cancer patients, accounting for 
90% of cancer-associated deaths [1]. Improving our understanding of metastatic development 
is essential to improve the outcomes of cancer patients. Decades of cancer research have 
described metastasis as a multi-step process by which cancer cells disseminate from the primary 
tumor to surrounding tissues and distant organs. Metastatic spread is mediated by a biological 
sequence in which metastatic cells invade surrounding tissue, disseminate to blood and 
lymphatic vessels, survive in the blood circulation, extravasate through the vascular wall, and 
colonize new organs [2]. This complex process implies that metastatic cells harbor distinct 
capacities that can be activated sequentially for progression through the metastatic stages. 
Primary tumors, which fuel metastatic development, are characterized by marked intratumoral 
heterogeneity. The origin of this cellular heterogeneity is mainly explained by the hierarchical 
organization of tumor tissues, where several subpopulations of self-renewing cancer stem cells 
(CSCs) maintain the long-term oligoclonal nature of the neoplasm [3]. A direct consequence is 
the pivotal role of CSCs in leading clinical evolution and metastatic progression [4-6]. Growing 
evidence indicates that CD95 is a key regulator of metastatic spread. Accordingly, this so-called 
death receptor is involved in the migration of cancer cells in triple-negative breast cancers 
(TNBCs) [7] and glioblastoma [8] as well as the survival and regulation of CSC fate [9].
Although CD95 is considered the prototype of the death receptors, this paradigm has been 
challenged. It is becoming clear that, similar to tumor necrosis factor receptor (TNFR)-1, CD95 
mediates non-apoptotic signaling pathways involved in many cellular processes including cell 
proliferation, survival, differentiation, and migration. This review focuses on the role of CD95 
and its ligand CD95L in cell migration [10]. 
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4Structural features of CD95 and its ligands
Death receptors of the TNFR superfamily include TNFR1, Fas (CD95), death receptor 3 (DR3), 
TNF-related apoptosis-inducing ligand receptors 1 and 2 (TRAIL-R1 and TRAIL-R2), death 
receptor 6 (DR6), nerve growth factor receptor (NGFR), and ectodysplasin receptor (EDAR). 
These receptors share an intracellular death domain (DD) that is required for their apoptosis-
inducing activity [11]. Although the non-apoptotic functions of CD95 were reported soon after 
its cloning [12], they have been neglected over the years, as research efforts focused on 
deciphering the molecular basis of apoptosis induction by CD95 and the biological functions 
of CD95 in light of this role [13, 14]. 
CD95 is a 319 amino acid type I transmembrane glycoprotein [15, 16]. This receptor harbors 
extracellular amino-terminal cysteine-rich domains (CRDs) [17, 18] that define its ligand 
specificity [19] and a conserved 80 amino acid sequence located in the cytoplasmic tail called 
the death domain (DD) that is necessary for the induction of apoptosis [20, 21]. Its 
corresponding ligand, CD95L (FasL/CD178), is a type II transmembrane protein with a 
cytoplasmic domain, a transmembrane domain, a stalk region, and a C-terminal TNF homology 
domain (THD). The THD mediates both homotrimerization of CD95L and binding to CD95 
(Figure 1). This transmembrane ligand (m-CD95L) can be cleaved at the stalk region by several 
metalloproteases (MMPs), namely, MMP3, MMP7, MMP9, and a disintegrin and 
metalloprotease domain-containing protein (ADAM)-10 [22], or at the THD by plasmin [23]. 
The resulting soluble form of CD95L (s-CD95L) is released into the bloodstream as a 
homotrimer [24]. s-CD95L can interact with CD95 but does not induce cell death, and was 
initially thought to compete with its membrane-bound counterpart for CD95 binding [25, 26]. 
s-CD95L accumulates in the bloodstream of patients with various pathologic conditions, 
including certain cancers such as NK cell lymphomas [27] and TNBC, in which s-CD95L levels 
are associated with the risk of relapse [7]. 
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5CD95-mediated cell signaling pathways
The interaction of m-CD95L with CD95 leads to the recruitment of the adaptor protein Fas-
associated protein with death domain (FADD) via homotypic DD-mediated interactions. FADD 
recruits the protease caspase-8 and the long form of the regulator of apoptosis cellular FADD-
like interleukin-1-β-converting enzyme-inhibitory protein (cFLIPL) via death effector domain 
(DED)-mediated interactions. Together, these proteins form the death-inducing signaling 
complex (DISC) (Figure 2) [28]. Tumor necrosis factor receptor-associated factor 2 (TRAF2) 
can interact with caspase-8 at the DISC [29]. TRAF2 induces K48-linked polyubiquitination of 
caspase-8 and its rapid proteasomal degradation, protecting cells from death decisions [29]. In 
addition, TRAF2 orchestrates the implementation of non-apoptotic signaling pathways 
including NF-B by interacting with c-IAP1/2 [30, 31]. 
CD95 stimulation can induce apoptotic and non-apoptotic signaling pathways. The apoptotic 
signaling pathway is abrogated before completion in most cancer cells, suggesting that, in these 
cells, the CD95-mediated non-apoptotic signaling pathways including NF-B and the p38, 
ERK, and JNK MAPKs promote cell proliferation, survival, and migration and cytokine 
production [32]. The CD95-mediated apoptotic and non-apoptotic signaling pathways share 
many factors such as the apoptotic factors FADD and caspase-8, which are also required for 
NF-B activation upon m-CD95L stimulation [32, 33]. Unlike m-CD95L, s-CD95L does not 
efficiently recruit FADD and caspase-8, and thus fails to trigger the DISC and the subsequent 
apoptotic program. Our group and others showed that binding of the trimeric s-CD95L to CD95 
induces the formation of an alternative signaling complex that results in cell migration, which 
we therefore designated as the motility-inducing signaling complex (MISC) (Figure 2) [7, 34]. 
MISC formation relies on the recruitment of phospholipase C1 (PLC1) to a membrane-
proximal intracellular domain of CD95 that has been designated calcium-inducing domain 
(CID). PLC1 generates inositol triphosphate (IP3) and induces the release of endoplasmic 
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6reticulum (ER) calcium stores by activating IP3 receptors. The intracellular increase in calcium 
(Ca2+) activates a store-operated current (SOC) through the plasma membrane Ca2+ channel 
ORAI1, resulting in Ca2+ entry close to CD95 and limiting the recruitment of FADD and 
caspase-8 by activating protein kinase C 2 [35]. The recruitment and activation of NADPH 
oxidase 3 in the MISC triggers reactive oxygen species production, resulting in the activation 
of the src kinase designated c-yes and the subsequent induction of cell migration. This pathway 
has been observed in T cells, TNBC cells, and glioblastoma cells [8, 36, 37]. 
CD95/CD95L and immune homeostasis
Although the CD95/CD95L pair exerts pleiotropic effects in physiological and pathological 
contexts that will be discussed in this review, the main role of this couple involves the regulation 
of the adaptive immune response [38]. Lpr (lymphoproliferation) mice harbor a transposable 
element inserted into intron 2 of CD95 encoded by the APT1 gene that prematurely terminates 
CD95 transcription [39]. Gld (generalized lymphoproliferative disease) mice express a mutated 
CD95L in which the phenylalanine at position 273 is replaced by leucine (F273L), resulting in 
reduced affinity for CD95 [40]. Lprcg mice (lpr gene complementing gld) bear a mutation within 
the CD95 DD (N238V) that impinges on FADD recruitment and the induction of apoptosis 
[41]. Knock-in mice in which full length CD95L was replaced by its soluble counterpart 
revealed that the non-apoptotic ligand causes a severe lupus-like autoimmune disorder and 
promotes carcinogenesis [42]. These lupus-prone animal models, which are characterized by 
lymphadenopathy and splenomegaly, with an accumulation of CD3+CD8-CD4- double-
negative T (DNT) cells, revealed the pivotal role of the CD95L/CD95 pair in immune 
homeostasis. Consistent with these animal models, several germinal mutations of CD95 in 
humans are causative for autoimmune lymphoproliferative syndrome (ALPS) type Ia (also 
known as ALPS-FAS) [43]. ALPS patients show chronic lymphoproliferation, 
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7lymphadenopathy, and/or splenomegaly and an aberrant accumulation of DNT cells. Because 
they share many symptoms with lupus patients, ALPS patients are often initially diagnosed 
with lupus. ALPS-FAS patients exhibit heterozygous germline mutations in APT1 that are 
mainly located in the DD; such mutations prevent the induction of CD95-mediated apoptosis, 
whereas they allow non-apoptotic signaling [44, 45]. Animal models and ALPS patients 
confirm the pivotal role of CD95 in immune homeostasis, and suggest that its non-apoptotic 
signaling function contributes to inflammation and oncogenesis.
CD95 is responsible for immune contraction by mediating the apoptotic deletion of activated T 
cells in the periphery, a process called activation-induced cell death (AICD) [46-49]. Re-
expression of CD95 in the T cells of lpr mice prevents lymphoproliferation associated with the 
accumulation of DNT cells but does not prevent autoimmunity [50, 51]. On the other hand, loss 
of CD95L in T cells favors the accumulation of CD11c+ dendritic cells (DCs) and B cells, 
thereby contributing to prolonged antigen presentation, and is responsible for the autoimmune 
disorder [52]. In addition to its pro-apoptotic role, CD95L expression in memory CD4+ or CD8+ 
T cells can induce a CD95-mediated PI3K/Akt signaling pathway in naïve T cells, altering their 
differentiation and activation. This represents an alternative route for CD95 to terminate the 
immune response in addition to AICD [53]. This CD95-mediated non-apoptotic process is 
designated “precocious differentiation”.
CD95-mediated cell migration and calcium (Ca2+)
Ca2+ is a universal and versatile second messenger involved in the activation of pleiotropic 
signaling cascades [54, 55]. Ca2+ pumps, channels, and exchangers and Ca2+-binding proteins 
present at the plasma membrane and in different cellular compartments (ER, lysosome, 
mitochondria, and Golgi apparatus) tightly regulate the [Ca2+]cyt, which is close to 100 nM in 
the resting state [56-60]. In response to various stimuli, [Ca2+]cyt can reach concentrations of 
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810 μM and higher in microdomains, including the interface between the ER and the 
mitochondria (mitochondria-associated ER membrane or MAM) [56] or beneath the plasma 
membrane. This increased [Ca2+]cyt can be evoked by mobilizing Ca2+ from intracellular stores, 
such as the ER and Golgi apparatus (Figure 3), or through Ca2+ entry from the extracellular 
environment via Ca2+ channels, such as Voltage-Gated Calcium (VGC) channels or SOC 
channels (Figure 3). Upon elevation of [Ca2+]cyt, energy-dependent active transporters, 
including pumps and exchangers, work to refill stores and reset Ca2+ levels to the resting state 
(Figure 3). 
Most of the hallmarks of cancer, if not all, involve Ca2+ signaling, which mediates critical 
cellular processes such as therapeutic resistance [61], metastasis, bypass of apoptosis [62], and 
breast CSC enrichment [63]. CD95 engagement leads to a rapid, localized, and transient 
increase in [Ca2+]cyt [64-66], which negatively controls CD95 apoptotic signaling [35], and 
promotes cell migration [34] and metastasis [7] through a c-yes/PLC1/IP3/SOC 
channels/Ca2+/PI3K signal (Figures 2 and 3). The versatility of Ca2+ as an intracellular 
messenger stems largely from its complex spatiotemporal organization of the Ca2+ signals. 
Spatiotemporal calcium patterns 
Ca2+ signaling regulates multiple aspects of adaptive metastatic cancer cell behaviors, including 
migration, local angiogenesis induction, intravasation, and epithelial-mesenchymal transition 
(EMT) [67]. EMT is a central process required for normal embryonic development that not only 
contributes to metastatic dissemination [68], but is also involved in the chemotherapy resistance 
of cancer cells [69]. 
[Ca2+]cyt plays a key role in directional sensing, as oscillations in [Ca2+]cyt activate cytoskeletal 
remodeling, actin contraction, and focal adhesion (FA) turnover necessary for changes in 
contractility and directional movement (Figures 3 and 4). Cell movement begins with the 
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9formation of protrusions of the cell membrane (lamellipodia, filopodia, and podosomes), 
followed by the establishment of new FAs at the leading edge to anchor the cytoskeleton to the 
extracellular matrix (ECM). Traction forces move the cell forward, and the cycle ends with 
disassembly of the FA at the cell rear [70, 71]. Most of these events are spatiotemporally 
regulated by Ca2+ signaling [72, 73]. Indeed, oscillations of cytosolic Ca2+ induce actin 
remodeling through the activation of the small GTPases RhoA, cdc42, and Rac1, which are 
activated in cells exposed to s-CD95L [74] (Figure 3). During the rear-to-end retraction phase, 
actomyosin contraction is regulated by phosphorylation of the myosin light chain (MLC) 
mediated by the calmodulin Ca2+-dependent kinase MLCK (Figure 3) [67, 75]. Finally, the 
disassembly of the FA is controlled by calpains, which are Ca2+-dependent proteases (Figure 
3) [76]. During migration, polarized cells exhibit a cytosolic Ca2+ gradient in which Ca2+ 
concentration is low at the leading edge [77]. This gradient is produced by increased activity of 
the plasma membrane calcium ATPases (PMCA pumps) at the leading edge to extrude 
intracellular Ca2+ [78] (Figure 4). This low intracellular Ca2+ concentration allows the different 
components of the cell migration machinery to respond to local and transient Ca2+ spikes called 
“Ca2+ flickers” at the front of the migrating cells (Figures 3 and 4). These “pulses” locally 
promote the disassembly of FA proteins [79], and steer the migrating cell in the direction of the 
chemoattractant [80]. In migrating cells, mitochondria actively move along cytoskeletal 
filaments to different cellular topographies with high energetic demands (Figure 4). In addition 
to ATP production, one of the main functional roles attributed to mitochondria is the ability to 
spatially remodel intracellular Ca2+ signaling. Accordingly, inhibition of the mitochondrial Ca2+ 
uniporter (MCU) by ruthenium red or specific small interfering RNAs induces mitochondrial 
depolarization in the triple-negative breast adenocarcinoma cell line MDA-MB-231, inhibiting 
SOC Entry (SOCE) through Orai1/STIM1 channels and abrogating cancer cell migration [81]. 
In summary, hotspots of Ca2+ are crucial for cell migration and cell steering, and rely on many 
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cellular factors including SOCE [78, 79] and the activity of stretch-activated calcium channels 
(SAC) [77, 80]. 
Non-apoptotic effect of CD95 engagement and Ca2+ response
Many highly invasive cancer cell types possess specialized matrix-degrading organelles called 
invadopodia [82, 83]. Invadopodia are dynamic actin-based cell protrusions composed of an 
actin core surrounded by integrins and actin-associated proteins. The assembly of invadopodia 
is initiated in response to the focal generation of phosphatidylinositol bi and trisphosphate (PIP2 
and PIP3) and the activation of the nonreceptor tyrosine kinase Src [84-86]. The assembled 
invadopodia recruit proteolytic enzymes, such as membrane type 1 (MT1)-matrix 
metalloproteinase (MMP), MMP2, and MMP9, via localized Ca2+ influx through SAC [87-89] 
and extracellular medium acidification through the Na+/H+ exchanger NHE1 [90] to facilitate 
the focal degradation of the ECM and cell invasion [91] (Figure 4). The membrane-bound 
apoptotic CD95L is cleaved by these MMPs [92] to generate the pro-migratory s-CD95L, which 
in turn induces CD95-mediated NHE1 activation [74]. 
s-CD95L induces the formation of migrating pseudopods at the leading edge of which the 
engaged CD95 and SOC channels are capped [34]. Therefore, the Ca2+ response that promotes 
CD95-mediated cell motility does not display a homogeneous cytosolic distribution, but instead 
results in Ca2+ microdomains localized at the leading edge of the cell protrusion emitted by the 
migrating cells [34]. CD95L-induced cell migration depends, at least in part, on another Ca2+ 
microdomain between the ER and mitochondria called MAM. The anti-apoptotic factors Bcl-2 
and BclxL, which are localized in these intracellular compartments, collaborate to induce 
CD95-mediated mitochondrial Ca2+ upload, increasing ATP production and thereby promoting 
cell migration [93]. Capping of CD95 is associated with F-actin polarization in activated T 
cells, and this process occurs independently of the apoptotic program because inhibition of actin 
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polymerization using cytochalasin D prevents CD95 capping without affecting DISC formation 
[94]. CD95 capping requires activation of the serine/threonine kinase Rho kinase (ROCK) [94], 
which is also necessary to activate NHE1 in cells exposed to s-CD95L [74]. In the fibroblast 
cell line PS120, s-CD95L enhances cell migration by activating NHE1 via Akt and RhoA-
dependent but Ca2+-independent pathways [74]. This does not rule out the participation of 
STIM1/Orai1 in CD95L-mediated PS120 cell migration, and Ca2+-independent effects of 
STIM1/Orai1 on cell migration were recently described in relation to the RhoA/ROCK/MLC 
transduction pathway [95-97]. Interaction of these proteins, which colocalize in the CD95 cap, 
would be sufficient to trigger the effects of CD95L on cell migration. 
 NHE1 catalyzes an electroneutral exchange of extracellular Na+ for intracellular H+, and its 
activity is necessary for cell migration [98, 99]. The NHE1-driven increase in intracellular pH 
affects cell migration by changing the structure of cofilin, presumably through the 
deprotonation of His133, and impairing its recruitment by phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2), thus stimulating its actin-severing activity [100] (Figure 4). Increased assembly of a 
branched actin filament network requires filament severing to increase the abundance of actin-
free barbed ends, and is a driving force for membrane protrusion through a cofilin and Arp2/3-
dependent mechanism [101] (Figure 4). Cortactin recruits the adaptor protein Nck1, which in 
turn binds N-WASP, and cofilin [102]. This molecular complex is disrupted through src kinase-
dependent phosphorylation of cortactin and NHE1-dependent pH increase [103] to release 
cofilin, which promotes actin polymerization and invadopodia formation (Figure 4). NHE1 
activity is also instrumental for the activation of central determinants of cell polarity such as 
cdc42 [98]. Activation of PLCγ, which hydrolyzes PI(4,5)P2, is necessary for cofilin-dependent 
actin-free barbed end formation [104]. Interaction of s-CD95L with CD95 triggers the rapid 
accumulation of the receptor at the leading edge of motile cells [34, 105], and activates PLCγ1 
[34] and NHE1 [74], engendering a cell migration program that requires cofilin [106]. 
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Activation of cell migration and survival mediated by CD95 relies on the recruitment of 
receptor tyrosine kinases (RTKs) including epidermal growth factor receptor (EGFR) [7, 107] 
and platelet-derived growth factor receptor (PDGFR) [106] and the subsequent activation of 
members of the src kinase family. 
Adhesion and regulation of CD95-mediated cell death 
We and others observed that CD95L is ectopically expressed by endothelial cells covering 
blood vessels in inflamed organs of lupus patients [37] and in tumor tissues [7, 108], suggesting 
that CD95L could serve as a barrier [108], a chemoattractant following its shedding by 
metalloproteases [37, 109], or an adhesion molecule for the recruitment of neutrophils [110]. 
Indeed, Coukos and colleagues report that CD95L expression by endothelial cells in tumor 
tissues represents a physical barrier, killing CD8+ T cells while sparing T regulatory (Treg) 
cells, whose accumulation in the tumor might cause an immunosuppressive environment [108]. 
Nonetheless, the transmembrane CD95L at the surface of endothelial cells also has non-
apoptotic functions, as it promotes the binding and recruitment of myeloid cells by inducing 
rolling, adhesion, and transmigration processes [110]. Therefore, CD95L expression by 
endothelial cells is instrumental for mounting an efficient anti-infectious response [110]. After 
metalloprotease-mediated cleavage, the generation of a s-CD95L gradient promotes the 
trafficking of pro-inflammatory Th17 cells in inflamed organs of lupus patients, thereby 
contributing to aggravate their clinical symptoms [37]. This s-CD95L gradient in TNBC 
patients favors migration of cancer cells and increases the risk of metastasis [7]. 
The expression of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells is a marker of 
poor prognosis in colorectal cancer [111]. CD95L expression by endothelial cells controls neo-
angiogenesis through a PAI-1-dependent mechanism [23]. PAI-1 is the inhibitor of urokinase-
type plasminogen activator (uPA), which converts plasminogen into its active form, plasmin. 
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Plasmin in turn can cleave CD95L in its trimerization domain at Arg144-Lys145, releasing a 
cytotoxic ligand that eliminates endothelial cells and abrogates neo-angiogenesis [23]. PAI-1 
overexpression inhibits this process and promotes neovessel formation in cancers.
Overall, these studies raise the question of the exact role of CD95L in endothelial cells covering 
neovessels, and suggest that the co-expression of certain metalloproteases/PAI-1 may account 
for these pleiotropic roles. 
Alteration of adherens junctions in epithelia is associated with loss of cell-cell contacts, an 
initial step in EMT and the metastatic dissemination of carcinoma cells [112]. Loss of these 
contacts generates a cell death program that depends on CD95 [113]. Hueber et al. recently 
showed that the C-terminal domain of CD95 is important for the distribution of the receptor 
within adherens junctions in epithelial cells [113]. This region of CD95 also interacts with the 
polarity molecule Dlg1, thereby preventing DISC formation [113]. Depolarization of CD95 and 
its dissociation from Dlg1 and E-cadherin might represent a control mechanism to eliminate 
abnormal cells within epithelial tissues, thereby preventing the initial step of metastatic 
dissemination. The ERM proteins (ezrin, radixin, and moesin) are found in the microvilli, 
filopodia, membrane ruffles, and cell-to-cell contact sites, where they colocalize with actin and 
connect various cell-surface proteins to the actin cytoskeleton (Figure 4). Similar to Dlg1, ezrin 
interacts with the C-terminal PDZ-binding site of CD95 [105]; however, Dlg1 binding to CD95 
prevents DISC formation, whereas ezrin interaction with the receptor is instrumental for 
implementing the apoptotic program, at least in activated CD4+ T cells [105]. 
The link between CD95 and the cytoskeleton could reflect different stages of tumor 
development. Peter et al. showed that cancer cells with mesenchymal markers have a strong 
link between CD95 and the actin cytoskeleton and are sensitive to actin disruptors (i.e., 
cytochalasin D), whereas epithelial cells exhibit a stronger association between CD95 and 
microtubule structures and are sensitive to microtubule-disrupting compounds [114]. 
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Most of the studies on the cytoskeleton and CD95 focus on the apoptotic outcome and neglect 
to evaluate the obvious effect on cell migration and invasiveness.
Cell migration and the apoptotic machinery
Although caspase-8 is well-known as an apoptotic inducer, this zymogen also acts through its 
scaffolding function to drive cytokine production in various cancer cell lines upon m-CD95L 
stimulation [115]. Production of pro-inflammatory chemokines in dying cells results in the 
recruitment of monocytes and neutrophils that engulf the dying cells expressing the “find me” 
signal [116]. As recently detailed elsewhere [92], Src kinases phosphorylate multiple targets, 
and also mediate the recruitment of various RTKs such as EGFR into close proximity to CD95 
through mechanisms that remain to be elucidated. MISC formation leads to the activation of 
the PI3K/Akt pathway, which is instrumental for cancer cell migration [7]. Although caspase-
8 is not readily detected in the MISC by western blotting, it can be phosphorylated by Src on 
Y380, a molecular event that not only limits its activation but also promotes the recruitment 
and activation of the p85 regulatory subunit, initiating PI3K/Akt activation [117-119]. 
Although the CID is required for inducing the CD95-mediated Ca2+ response, PI3K activation 
is DD-dependent [34], suggesting that the CD95-mediated non-apoptotic signal stems from 
both the CID and the DD. 
Together with caspase-8, TRAF2 may also contribute to the CD95-mediated migration process. 
TRAF2 overexpression triggers a positive feedback loop in pancreatic tumor cells, because 
exposure to CD95L activates the NF-B signal, which in turn fuels TRAF2 overexpression in 
tumor cells [120]. In the presence of CD95L, pancreatic tumor cells overexpressing TRAF2 
induce the secretion of MMP2 and MMP9, uPA, and IL-8, factors involved in the invasive 
process. Although partial TRAF2-dependent inhibition of caspase-8 activation at the DISC 
level is required for the secretion of IL-8 and uPA and cell migration, complete abrogation of 
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caspase activity using the pharmacologic inhibitor zVAD-fmk blocks invasiveness, strongly 
supporting that the fine-tuned regulation of caspase activity orchestrates the cellular response 
[120]. 
Cancer stem cells and CD95 
Increasing evidence supports the existence of functionally distinct subsets of CSCs within 
primary tumors with tumor-propagating and/or metastatic capacity [121]. This functional 
heterogeneity within the CSC population was first described in pancreatic cancers, in which 
CXCR4 expression defines two different CD133+ CSC subsets. The CD133+CXCR4- 
population solely maintains the tumorigenic potential of the primary tumor, whereas the 
CD133+CXCR4+ cell population is essential for metastatic development [122]. A similar 
subpopulation of colorectal CSCs expressing CD26 was identified as the population responsible 
for liver metastasis, and was predictive of distant metastasis in patients [123]. The origin of this 
functional heterogeneity within the CSC population recently evolved with the notion of CSC 
state plasticity. In this regard, metastatic CSCs and non-metastatic CSCs may not be two 
distinct populations, but rather represent a gradient of stem cell programs that are expressed at 
higher or lower levels in response to intracellular and intercellular signals [124]. EMT plays an 
essential role in these CSC transition states [125, 126]. This concept was demonstrated by Liu 
et al., who showed that breast CSCs are highly plastic, transiting between two different cell 
states: a more proliferative epithelial-like state characterized by expression of ALDH, and a 
more invasive mesenchymal-like state characterized by the expression of the CD44+/CD24- 
phenotype [127]. Over the last decade, the connection between CSCs and EMT attracted 
considerable attention [128]. Studies initially suggested that overexpression of EMT 
transcription factors was sufficient to generate CSCs [129, 130]. However, cumulative clues 
indicate that cancer stemness and EMT are in fact convergent concepts by which the EMT 
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process confers CSCs the ability to switch between two CSC states. Although recent findings 
raise doubts about the critical role of EMT during metastasis in mouse models of breast and 
pancreatic cancers [69, 131], evidence supports that EMT is alternatively switched on during 
the first step of metastatic spread (tissue invasion, circulation in blood, and extravasation), and 
then switched off to allow the metastatic colonization of new organs. This cell plasticity was 
directly observed by intravital microscopy, confirming the role of epithelial-mesenchymal 
plasticity in metastatic development [132].
In this context, a thorough understanding of the associated tumor microenvironment factors that 
control the balance between the different CSC states is required to improve our understanding 
of metastatic disease. Emerging evidence suggests that tumor-infiltrated immune cells may play 
this role, bringing back the “seed and soil” hypothesis of S. Paget [133]. Myeloid-derived 
suppressor cells (MDSCs) are a subset of immature myeloid cells that can be recruited to tumor 
sites and display immunosuppressive activity [134]. Ouzounova et al. used mammary tumor 
models to demonstrate that monocytic (M-MDSCs) and granulocytic (G-MDSCs) subsets of 
MDSCs regulate spatiotemporal tumor cell plasticity. M-MDSCs facilitate tumor cell 
dissemination from the primary site by inducing EMT, whereas pulmonary G-MDSC infiltrates 
support metastatic colonization by reverting the EMT process [135]. Consistent with this idea, 
the IL-1β inflammatory response facilitates invasion and extravasation of metastatic-initiating 
cells by promoting EMT, and this signaling must be shut down at the metastatic site to induce 
EMT reversion and secondary tumor formation [136]. Similarly, neutrophils specifically 
support metastatic initiation by priming pre-metastatic sites, and neutrophil-derived 
leukotrienes aid the colonization of distant tissues by selectively expanding the sub-pool of 
cancer cells that acquire a stemness phenotype and retain high tumorigenic potential [137]. 
In mice, MDSCs are characterized by the expression of CD11b+Gr-1+ cell markers; G-MDSCs 
show CD11b+Ly6G+Gr-1High staining, whereas M-MDSCs show a CD11b+Ly6C+Gr-1Low 
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phenotype. The homeostasis of these myeloid cells relies on CD95L expression because loss of 
CD95L in mice leads to an increase in these populations [138]. Resistance to immunotherapy 
including the checkpoint inhibitors anti-CTLA4 and anti-PD1 in a melanoma mouse model is 
associated with increased infiltration of G-MDSCs expressing CD95L, which eliminates 
activated anti-tumor CD95high-expressing CD8+ T cells [139]. Another study showed that 
CD95L deficiency skews tumor-infiltrating MDSCs from G-MDSCs to the M-MDSC subset, 
which displays high immunosuppressive activity mostly through the overexpression of PD-L1 
[138]. These results emphasize the pivotal role of the CD95/CD95L pair in modulating the 
immune landscape by recruiting immunosuppressive cells within the primary tumor and/or 
participating in the elimination of anti-tumor CD8+ T cells. Nonetheless, the cells in tumor 
tissues that express CD95L and modulate the “soil” and, the CD95-dependent molecular 
mechanisms involved in the cancer/immune cell unbalance remain to be elucidated; recent data 
indicate that endothelial cells covering neovessels could represent the major source of CD95L 
[7, 108], .
Marcus Peter and colleagues proposed that CD95 stimulation can also modulate the phenotype 
of the “seed” itself. Accordingly, CD95 stimulation in various cancers (i.e., colon, breast, and 
renal cancer cell lines) induces a conversion from non-CSCs to CSCs through an apoptotic-
independent program, and in addition renders these cells resistant to the CD95-mediated 
apoptotic program [140]. From a molecular standpoint, CD95 stimulation in cancer cells 
induces the secretion of type I interferons (IFNα or IFNβ), which interact with IFN type I 
receptors (IFNAR1 and IFNAR2) and activate STAT1-promoting cancer stemness [9]. These 
experiments confirmed that CD95 is not a receptor uniquely able to implement cell death; 
however, the downstream molecular mechanisms controlling the implementation of cell death 
at the expense of this non-apoptotic and stemness response and vice versa remain unclear.
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Taken together, these studies suggest that the “seed and soil” concept needs to be revised to fit 
the concept of CSC state plasticity, and the CD95/CD95L pair might affect both seed and soil 
properties affecting cancer cell fate decisions and function. This assumption, if validated, will 
strengthen the use of CD95/CD95L inhibitors to improve cancer care. 
Conclusion and therapeutic perspectives
Spatiotemporally coordinated calcium gradients generated by SOCs and SACs, calcium efflux 
systems, and calcium microdomains orchestrate cellular behaviors as complex as directional 
cell movement. CD95 participates in this phenomenon by activating localized Ca2+ influx 
through SOCs. The effect of CD95 engagement on SAC activity has not been described to date; 
however, CD95 is linked to structures such as lipid rafts/caveolae or the cytoskeleton, which 
contribute to the activation of these channels. In muscle fibers, for example, similarities in 
electrophysiological properties and sensitivity to pharmacological inhibitors suggest that SOC 
and SAC belong to the same channel population or share common constituents, suggesting that 
both channels express the TRPC1 protein [141]. This mechanosensitive SOC regulates the cell 
polarity involved in the migration of human bone osteosarcoma cells [142] and breast cancer 
cells (for review, see [143]). Future investigation of a potential molecular link between CD95 
and the mechanosensitive channels would open new avenues to better understand the 
relationship between cell migration and the pathophysiological functions of the so-called death 
receptor.
The capability of proteinases to catalytically cleave substrate proteins post-synthesis is essential 
for sustaining life in all of its forms, from viruses to humans. Limited, site-specific proteolysis 
is an important post-translational modification, especially because this post-translational 
modification, in contrast to others, is irreversible under physiological conditions. The fact that 
two forms of CD95L exist and are associated with the presence or absence of MMPs raises the 
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question of what and where metalloproteases cleave CD95L. Similar to TNF, which is 
processed by TACE (ADAM-17) [144, 145] to release a soluble and inflammatory factor, 
CD95L-cleaving MMP(s) cause a signaling shift that transforms the apoptotic ligand into a pro-
inflammatory factor. Targeting soluble CD95L, its non-apoptotic signaling pathways, or the 
MMPs responsible for its cleavage may represent a novel therapeutic strategy to alleviate 
clinical symptoms in chronic inflammatory disorders such as lupus or to prevent metastatic 
dissemination in cancer patients. In this context, a “niche therapy” based on CD95-oriented 
targeting of the CSC-niche signals may be a potent alternative to prevent tumor progression 
[146].
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Figure legends
Figure 1. CD95 and CD95L structures. The death receptor CD95 encompasses three amino-
terminal cysteine-rich domains (CRDs) and is expressed at the plasma membrane as a 
homotrimer through homotypic interactions occurring via its Pre-Ligand Assembly Domain. 
Binding of its cognate ligand CD95L induces receptor oligomerization and triggers pro-
apoptotic signals through its death domain (DD). CD95 also implements an anti-apoptotic Ca2+ 
response through its calcium-inducing domain (CID). CD95L is a type II transmembrane 
protein harboring a unique proline-rich domain (PRD) for the recruitment of SH3 and WW 
domain-containing proteins. Membrane-bound CD95L (m-CD95L) binds to CD95 through 
cell-cell contact and induces cell death. Certain metalloproteases can release a soluble and non-
cytotoxic CD95L designated s-CD95L for soluble CD95L. The self-assembly domain (SA) is 
required for trimerization of the ligand. Plasmin can cleave CD95L, releasing a soluble and 
cytotoxic ligand. The TNF homology domain (THD) region of CD95L is responsible for CD95 
binding.
Figure 2. s-CD95 and m-CD95L trigger different CD95-mediated signaling pathways. A. 
Interaction of transmembrane CD95L (m-CD95L) with CD95 favors the recruitment of FADD 
to the death domain (DD) of CD95. FADD binds procaspase-8 and FADD-like IL-1β-
converting enzyme-inhibitory protein (cFLIP) to form the Death-Inducing Signaling Complex 
(DISC). Oligomerization of procaspase-8 promotes its autocatalytic activation and the release 
of a mature tetramer to the cytosol, which implements the apoptotic response. B. Stimulation 
of CD95 by soluble CD95L (s-CD95L) induces the recruitment of the PLC1 to the CD95 
Calcium-Inducing Domain (CID). The phospholipase generates inositol triphosphate (InsP3) by 
hydrolyzing phosphoinositol bisphosphate (PIP2). InsP3 activates IP3-R present at the 
membrane of the endoplasmic reticulum (ER) releasing Ca2+. This calcium response is 
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enhanced through the activation of the ORAI1 channel. The increased concentration of Ca2+ 
underneath the plasma membrane activates PKC-β2, which interferes with the recruitment of 
FADD to the DISC. In the MISC, NADPH oxidase 3 (NOX3) is also recruited and produces 
reactive oxygen species (ROS), which activate c-Yes. This Src kinase can recruit receptor 
tyrosine kinases and phosphorylate different proteins localized in the MISC that are responsible 
for PI3K/Akt signaling pathway activation and cell migration.
Figure 3. Spatial and temporal regulation of intracellular Ca2+ concentration control cell 
migration. In the front, CD95 engagement induces the activation of phospholipase Cγ (PLCγ), 
leading to the activation of inositol triphosphate (IP3) receptors and the depletion of calcium 
from the endoplasmic reticulum (ER). This in turn stimulates the calcium sensor STIM1, which 
transactivates the ORAI1 channel and induces store-operated calcium (SOC) entry. This 
localized SOC entry promotes the autophosphorylation of Focal Adhesion Kinase (FAK397) via 
activation of calcium-dependent PKCβ in the front and the degradation of (FAK) in the rear by 
the calcium-dependent µ-calpain protease, enhancing focal adhesion (FA) turnover and 
polarized cell motility. In the rear, local Ca2+ pulses activate Rho-associated protein kinase 
(ROCK) and myosin light chain kinase (MLCK), which phosphorylates myosin II for proper 
actin treadmilling and recycling. In the front, the Pyk2/rac1 pair regulates cytoskeleton 
organization via a calcium-dependent mechanism. DAG: diacylglycerol; PMCA: plasma 
membrane Ca2+-ATPase.
Figure 4. Model for steering a migrating cell. During migration, cells exhibit a typical rear-
to-front polarization. A [Ca2+] gradient is observed in the polarized cell by which high [Ca2+] 
at the back and low [Ca2+] at the leading edge facilitate the formation of functional local Ca2+ 
pulses. This [Ca2+] gradient is ensured by the accumulation of the plasma membrane Ca2+ 
Ac
ce
pte
d m
an
us
cri
pt
33
ATPase (PMCA) pump and intracellular Ca2+ compartments (ER, mitochondria) at the cell 
leading edge, which mediate Ca2+ extrusion and pumping, respectively. Intracellular Ca2+ entry 
controlled by a CD95-induced ORAI1-dependent mechanism establishes local Ca2+ 
flickers/pulses at the leading edge. Stretch-activated channels (TRPM7 and TRPV) are involved 
in the polarized calcium influx in migrating cells. CD95-stimulated NHE1 activity increases 
intracellular pH and promotes actin polymerization through a cofilin-dependent mechanism. 
Cdc42, a small pH-dependent Rho-GTPase, regulates actin polymerization by binding to the 
neural Wiskott-Aldrich syndrome protein (N-WASP), which activates the Arp2/3 complex. H+ 
extruded by NHE1 causes extracellular acidification, which promotes the activity of matrix 
metalloproteinases (MMPs). Ca2+ influx through ORAI channels stimulates calpain to cleave 
cortactin. ERM: Ezrin Radixin Moesin, FA: Focal Adhesion.
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